nida supported the development of the three medications that are currently approved for the treatment of opioid addiction, methadone and naltrexone. there's strong evidence of these medications in the treatment of opioid abuse disorders, in the prevention of overdoses, in the prevention of infections such as hiv and hepatitis-c. despite the strong evidence, less than 40% of those being treated for opioid addiction receive these medications. thus, expanding the access to medications for addiction is a critical part of the hhs strategy. towards this end, fund research for implementation strategies for medications, in substance treatment programs in the health system and in criminal justice settings. examples in health care include initiate i initiating new medications in the emergency room and the management of these medications within infectious disease clinics. examples in the clinical justice settings include administering new medications prior to the release or the use of vivtrol a once a month injection that blocks the action of heroin or other opioid drugs. nida also funds researc

i want to tell you what nida is doing on new approaches. we have been working on extended release medications. i will tell you about that. we focused on medications and we are pleased to have partnered in the release of a long acting vivatrol. we have been developing vaccines to keep drugs out of the brain so they won't have an impact. people will take these medications. but there's an issue. my patient has to make a decision every day whether they want to stay clean and sober, take medication, go to treatment or they want to not do that and head back into a path towards relapse. sometimes it's a conscious decision, sometimes not so conscious. but they need to make that decision every day. with a long-acting injectable form they don't need to make that too often. we are looking at an implantable bupa nor 6epinephrinnorepinephr. patients staying in the set are more compliant when they take it. it creates greater abstinence. that is one of the hopeful possibilities. i will point out this is submitted to the fda in september. it is under exped

to help address this nida in partnership with n.i.h. institute has created centers of excellence for the development of education curriculum for pain and substance abuse disorders. the urgency to address this epidemic is highlighted by the nearly 30,000 deaths from opioid overdose that occurred in 2014. the highest ever reported. solutions are already available. the challenge is their implementation. nida will continue to work closely with other federal agencies, community organizations, and private industries to address this complex challenges. >> thank you for inviting me here today. it's a great honor to talk with you about the real sense of advancing the nation's behavioral health and what we are doing to address the crisis. i want to thank the first panel. for providing great leadership. i know this crisis has had devastating consequences in all of your states, but i agree with you, mr. sessions, this is a winnable battle. you are already heard we are facing a treatment gap of unacceptable proportions. we will not stem the rising t

i want to tell you what nida is doing. i will tell you a little bit of that. we focused on medications and we are pleased tons have partneredn the release of a long-acting vivitra for. opioid addiction ad finally vaccines from keeping the drug out of the brain so that they don't have an impact. one of the issues is people will take medications but there's an issue, my patient has to make a decision whether they want to stay clean and sobber, stay in treatment, go the treatment or they want to not do that and head back into a path towards relapse. sometimes a conscious decision and sometimes not so conscious. with ao long-acting injectable form, they might not want to do quite as often. we are interested in the idea of a device that's long-acting inplant that only need to be implanted once every six months, so that o means only somebody hs to make a decision about their life and turning things around about once every six months in a fundamental way. patients are more likely to be compliant when they take this. so that's one of the hopeful possibilities. this wa

so i point that out to remind that y nida's job is to support what we can do today and chart a path forward what we can do tomorrow even better. s last challenge i will focus on is inch pimplementation. we've had some of these 15, 30 years. so he wh so what is going on? we are pleased to see increasing prescriptions. we've been pleased to try novel trials. the group at yale university emergency department noticed that she was seeing the same people over and over again coming in with either an overdose or with problems related to their hair win and other opioid issues. so she said maybe we can start them on it here in the emergency department. they're not taking our advice and going to the clinic, so why don't we act as the primary care physician. this is just one center. but we think that that is very promising and we're working right now on testing this in a number of other centers to see how it might be rolled out to emergency departments that want do this. not every place should, but those seeing a lot of opioid addicts might want do this. finally, i was really saddened by the story repr

director of nida. >> we started that dialogue with dea. in order for us to advance the science, we're going to have to be able to provide very specific product. >> i think that would be a huge deal. >> the doctor knows what a turning point this would be. >> studies that have used marijuana from the government have been very very helpful but perhaps somewhat limited as street product as gone through the roof in terms of pot ensy and strain type and i think the closer we get to studying real world scenarios in the lab the better off we're going to be. >> a real world scenario is what she was able to study. she didn't have to get the cannabis from old miss. patients bought their marijuana from a local dispensary. and now we get to see what the impact has been, her brain on cannabis. remember, she's been using marijuana every day for three months. >> what we see a -- >> the doctor found no evidence of impairment to her brain. there was a change over here in the cortex. it's a part of the brain responsible for decision making, emotion and empat

or fl nidaeative mik rdeidring ve mothd wi amynd air the two ug das hterto bnaurkio fasn i 20 11 tort sta anor agphane. ke mi a and pr astowere at the ca ifen odouagaugou tot meeew n lu vo.nteerse thr pasto calledmy aer aft es .caping cgunmentoame ines the rt tauran tishoo eng andonveryrae ton dehi. e thstpaomor sowehmi had ke's on ph e and,calledte wro amy.it ti was sll runclea ife mik su .rvived he anoterr am,icandw eard nkbuer,em frerged isom hm roo tao rtdeseoted hel y.lobb ingog tdownhe st.reet thand asis wea rthlly eom m entwh iend kinf oea rdlizeha tt th waere mes sogthinaj morly s.amis r >>r:eporte the12r-hou siege n bega hwhenlyeavied arml aqa edait mil,ants o twoemf th me won,rm stoheed tui bgsldinnd ase cat off r s.bomb inal pl, 28eople were llki,ed in g cludinaan cnadiaam fily of ur fo whoer we on a hitumannaria ip tr. 11 acamerins, ingncludi edward nkbu, erdemat i outal ive. mikeid rdering did not. uyot lefui qte aac legy rehe, i oncan lyma iginehe ten advsture u' yoavre hing now,ro wte amy's pofinal st.jo nathan vittgliobsi, cs, new lo .ndon > >> upxtne,di candaoutes crt

and the protocol for that is the screen pre-intervention referral to treatment about the that both nida and samhsa have abdicated for. >> image of the 1400 certified programs. as these programs are certified is there any effectiveness requirement that has to be demonstrated? how do we measure the effectiveness of any one of these 1400 programs? >> the regulations that specifically require that when asked about outcomes. we are looking into developing a process that would tie certification and recertification to patient outcomes. the regulations were put in place at a time with a technological infrastructure and the understanding of what the outcomes could be was limited. >> is very consistency among certified programs looking at the medical side, a counseling side, we do expect to go to any one of these 1400 certified programs in the country can see the same model? >> i would. and the reason i can say that -- >> dr. peirce is shaking her head. >> i would at the basis of it. because these programs are accredited by private nonprofit organizations in addition to being certified by the fed

and the protocol for that is screening brief intervention referral to treatment modality that both nida and samhsa have advocated for. >> you mentioned 1400 certified programs. as these programs are certified, is there any effectiveness requirement that has to be demonstrated? how do we measure effectiveness of any one of these 1,400 programs? >> the regulations don't specifically require that we ask about outcomes. we're looking into developing a process that would tie certification and recertification to patient outcomes. the regulations were put in place at a time when the technological infrastructure and the understanding of what the outcomes could be was limited. >> is there a consistency among certified programs, looking at the medical side, the counseling side, would you expect to go to any one of these 1,400 certify programs in the country and see the same model? >> i would. and the reason i can say that -- >> dr. peirce is shaking her head. >> i would at the basis of it, because these programs are accredited by private, nonprofit organizations in addition to being certified by